|
IN THEIR OWN
WORDS!
"
...that
the manufacturer submits and does not require a clinical trial.
"
" ...the vaccine
will be registered without clinical trials. "
The Drug Companies and the World Health
Organization
The following is from the WHO (World Health
Organization).
Transcript of WHO Virtual Press Conference of 6
August 2009 with
Dr. Marie-Paule Kieny,
Director of the Initiative for Vaccine Research at
WHO Headquarters and Gregory Hartl, Spokesperson for H1N1 "In terms of real production, the manufacturers have adapted
these vaccine viruses to grow
in their particular conditions, and they have produced lots of batches if you wish. So these are the material, it’s concentrated, it's an experimental vaccine that can be now used for clinical trials and some of the batches, the larger batches, are also the ones that will be used for real application and implementation of vaccination campaigns." "In the USA for example, the FDA approves a strain change by
looking at the quality
control dossier that the manufacturer submits and does not require a clinical trial. Therefore, for those pandemic vaccines that will be like a strain change, only it will be H1N1 instead of another seasonal strain, the FDA has decided that they will treat this as a normal strain change and, therefore, the vaccine will be registered without clinical trials." Source - Full Transcript:
The above listed file (and web link) was found
at this web page:
About Dr Marie-Paule
Kieny:
Please note, she is deep in the pharmaceutical industry. See
this quote in her bio ie:
"Dr Marie-Paule KIENY is the Director of
the World Health Organization (WHO) Initiative for
Vaccine Research, a position she has held since 2001. ...The
Initiative for Vaccine Research conducts and coordinates activities
related to product research and development and
implementation research for vaccines and delivery
devices."
|